This page summarizes information about the clinical trials that support investigation of both approved and experimental medicines. This information includes information about the interventions and their sponsoring organizations. Note that these data are derived from ClinicalTrials.gov, with information corrected and disambiguated to convey more accurate detail about these trials. Phase 4 trials are currently excluded on this page by default, as this data will be analyzed separately at a later date.
Trials with Experimental APIs
Top 5 (by most trials)
recombinant adenoviral human p53 gene (31) vm202 (17) aglatimagene besadenovec (11) veledimex (10) vocimagene amiretrorepvec (9)Trials with Approved APIs
Top 5 (by most trials)
onasemnogene abeparvovec (8) delandistrogene moxeparvovec (7) lentiglobin bb305 (6) valoctocogene roxaparvovec (6) voretigene neparvovec (5)Trials with Unapproved APIs
Top 5 (by most trials)
NoneAPIs in Phase 1
Top 5 (by most trials)
recombinant adenoviral human p53 gene (14) veledimex (8) vocimagene amiretrorepvec (7) vm202 (6) xt-150 (5)APIs in Phase 2
Top 5 (by most trials)
recombinant adenoviral human p53 gene (20) vm202 (15) delandistrogene moxeparvovec (6) valoctocogene roxaparvovec (6) golnerminogene pradenovec (6)APIs in Phase 3
Top 5 (by most trials)
alferminogene tadenovec (5) onasemnogene abeparvovec (5) gs010 (4) vm202 (4) oav101 (3)Phase 1 Sponsors
Top 5 (by most trials)
National Cancer Institute (NCI) (27) Ohio State University (19) University of Pennsylvania (18) University of Texas at Houston (12) Chinese Academy of Medical Sciences (12)Phase 2 Sponsors
Top 5 (by most trials)
National Cancer Institute (NCI) (17) University of London (13) Ohio State University (11) University of Pennsylvania (9) ViroMed (9)Phase 3 Sponsors
Top 5 (by most trials)
Novartis (5) Sarepta Therapeutics (5) Pfizer (4) AveXis, Inc. (4) Gene Biotherapeutics, Inc. (4)